Suppliers and packagers for generic pharmaceutical drug: TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-294-01	100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-294-01)	2015-02-25
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-294-10	1000 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-294-10)	2015-02-25
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-294-90	90 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-294-90)	2015-02-25
Glenmark Pharms Ltd	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE	trandolapril; verapamil hydrochloride	TABLET, EXTENDED RELEASE;ORAL	079135	ANDA	Glenmark Pharmaceuticals Inc., USA	68462-295-01	100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (68462-295-01)	2015-02-25

Trandolapril and Verapamil Hydrochloride Drug Substance Suppliers

Last updated: February 19, 2026

This analysis identifies key suppliers for the active pharmaceutical ingredients (APIs) trandolapril and verapamil hydrochloride, providing insights into their manufacturing capabilities, regulatory standing, and potential for supplying the global market. The identification of reliable API suppliers is critical for pharmaceutical companies engaged in the development, manufacturing, and commercialization of finished drug products containing these compounds.

Who Manufactures Trandolapril API?

Trandolapril is an angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure. Key manufacturers of trandolapril API include:

• Divi's Laboratories Limited: Divi's is a significant player in the API market, with established manufacturing sites in India. They possess multiple manufacturing units and have a strong regulatory track record, holding accreditations from agencies including the US FDA, EU EDQM, and others. Divi's production capacity for APIs is substantial, allowing for large-scale supply. Their quality management systems are designed to meet international standards.

• Sun Pharmaceutical Industries Ltd.: As one of the largest generic pharmaceutical companies globally, Sun Pharma is a vertically integrated manufacturer. They produce a range of APIs, including those for cardiovascular drugs. Sun Pharma operates multiple manufacturing facilities across India and other regions, compliant with cGMP standards and audited by major regulatory bodies. Their API business leverages their extensive R&D and manufacturing infrastructure.

• Laurus Labs Limited: Laurus Labs is an Indian API manufacturer with a focus on complex chemistries. They have demonstrated capabilities in producing APIs for various therapeutic areas. Their manufacturing facilities are approved by the US FDA and other international regulatory authorities. Laurus Labs emphasizes process innovation and cost-efficiency in its API production.

• Dr. Reddy's Laboratories Ltd.: This Indian multinational pharmaceutical company is involved in API manufacturing for both proprietary and generic products. Dr. Reddy's has a global manufacturing footprint, with facilities adhering to stringent quality and regulatory requirements. They are known for their expertise in chemical synthesis and process development for a wide array of APIs.

Trandolapril API Manufacturing Considerations

• Regulatory Compliance: Suppliers must have facilities inspected and approved by major regulatory agencies such as the US Food and Drug Administration (FDA), the European Directorate for the Quality of Medicines & HealthCare (EDQM), and others relevant to the target markets. This includes maintaining Drug Master Files (DMFs) or Certificates of Suitability to the Monographs of the European Pharmacopoeia (CEPs).
• Quality Control: Robust quality control measures are essential, including rigorous testing for purity, potency, and the absence of impurities. Analytical methods must be validated.
• Supply Chain Reliability: Manufacturers should demonstrate a consistent ability to meet demand, manage production schedules, and maintain inventory to avoid supply disruptions.
• Intellectual Property: Companies must ensure their manufacturing processes do not infringe on existing patents.

Who Manufactures Verapamil Hydrochloride API?

Verapamil hydrochloride is a calcium channel blocker used to treat hypertension, angina, and certain heart rhythm disorders. Key manufacturers of verapamil hydrochloride API include:

• Neuland Laboratories Ltd.: Neuland is an Indian API manufacturer with significant experience in producing APIs for various therapeutic classes, including cardiovascular drugs. Their manufacturing sites are US FDA, EDQM, and other international regulatory agency approved. Neuland focuses on complex chemistry and offers custom manufacturing services.

• Granules India Ltd.: Granules India is a global pharmaceutical company specializing in APIs, intermediates, and finished dosage formulations. They have a strong presence in the cardiovascular API segment. Their manufacturing facilities, primarily in India, are compliant with cGMP and are regularly inspected by global regulatory bodies. Granules emphasizes backward integration for key starting materials.

• Laurus Labs Limited: As noted for trandolapril, Laurus Labs also produces verapamil hydrochloride. Their expertise in chemical synthesis and established regulatory approvals make them a notable supplier for this API.

• Solara Active Pharma Sciences Limited: Solara is a global API manufacturer with R&D and manufacturing capabilities. They produce a range of APIs, including those for cardiovascular conditions. Solara's facilities are approved by major regulatory agencies, and they emphasize robust quality systems and efficient manufacturing.

• Industrias Farmaceuticas Alce, S.A.P.I. de C.V. (ALCE): Based in Mexico, ALCE is a manufacturer of APIs, including verapamil hydrochloride. Their facilities operate under cGMP guidelines and are subject to inspections by regulatory authorities. ALCE serves both domestic and international markets.

Verapamil Hydrochloride API Manufacturing Considerations

• Chirality: Verapamil is a chiral molecule, and different enantiomers may have varying pharmacological activity. Manufacturers must ensure control over stereochemistry if a specific enantiomer is required or if racemic mixtures are being produced.
• Polymorphism: Control over polymorphic forms of verapamil hydrochloride is crucial as different polymorphs can affect dissolution rates, bioavailability, and stability of the finished drug product.
• Impurity Profiling: Comprehensive identification and control of process-related impurities and degradation products are essential. Regulatory agencies require detailed impurity profiles.
• Scale-Up Capabilities: Manufacturers must demonstrate the ability to scale production from laboratory to commercial volumes while maintaining consistent quality and cost-effectiveness.

Supplier Landscape and Market Dynamics

The market for both trandolapril and verapamil hydrochloride APIs is characterized by competition among a number of established manufacturers, predominantly based in India, with some presence in other regions.

Key Trends:

• Increased Regulatory Scrutiny: Global regulatory bodies are increasing their oversight of API manufacturing, particularly regarding data integrity, impurity control, and supply chain security. Suppliers with strong, consistent regulatory histories are favored.
• Cost Pressures: Pharmaceutical companies continuously seek cost-effective API sourcing. Manufacturers that can optimize their processes for efficiency and yield are competitively positioned.
• Supply Chain Resilience: The COVID-19 pandemic highlighted the vulnerabilities of global supply chains. Companies are increasingly prioritizing suppliers with demonstrated resilience, robust business continuity plans, and diversified manufacturing capabilities.
• Geographic Diversification: While India remains a dominant supplier, there is a growing trend towards diversifying sourcing to mitigate geopolitical risks and ensure supply chain redundancy.
• Focus on Quality and Compliance: Generic drug markets, in particular, rely heavily on high-quality, compliant APIs to gain market approval and maintain patient safety. Suppliers must meet evolving quality standards.

Comparative Analysis:

API	Primary Manufacturers (Sample)	Geographic Concentration	Key Strengths
Trandolapril	Divi's Laboratories, Sun Pharma, Laurus Labs, Dr. Reddy's	India	Large-scale capacity, strong regulatory dossiers, integrated manufacturing.
Verapamil HCl	Neuland Labs, Granules India, Laurus Labs, Solara Pharma, ALCE	India, Mexico	Expertise in complex chemistry, chiral control, regulatory experience.

Both trandolapril and verapamil hydrochloride are mature APIs, meaning their patent protection for the molecules themselves has long expired. This has led to a competitive generic market, driving demand for reliable and cost-efficient API suppliers. The primary competitive factors for suppliers revolve around:

1. Cost of Production: Efficient manufacturing processes and economies of scale.
2. Quality and Regulatory Compliance: Maintaining high standards and successful regulatory inspections.
3. Security of Supply: Consistent availability and reliable delivery schedules.
4. Technical Expertise: Ability to handle complex synthesis and impurity control.

Key Takeaways

• The supply landscape for trandolapril and verapamil hydrochloride APIs is dominated by Indian manufacturers, with established players like Divi's Laboratories, Sun Pharma, Laurus Labs, Neuland Laboratories, and Granules India holding significant market positions.
• Suppliers must maintain rigorous adherence to international cGMP standards and possess active regulatory approvals from agencies such as the US FDA and EDQM.
• Key differentiators for API suppliers include production capacity, cost-efficiency, robust quality management systems, and demonstrated supply chain reliability.
• Verapamil hydrochloride manufacturing requires specific attention to chiral control and polymorphism, in addition to standard API quality considerations.
• Companies seeking to secure API supply should prioritize manufacturers with strong regulatory track records, demonstrated scalability, and a commitment to quality assurance.

FAQs

1. What is the primary geographic concentration of API manufacturers for trandolapril and verapamil hydrochloride? Indian manufacturers constitute the primary geographic concentration for both trandolapril and verapamil hydrochloride APIs.

2. Are there any specific manufacturing challenges associated with verapamil hydrochloride production? Yes, verapamil hydrochloride manufacturing requires careful control over its chiral nature and potential polymorphism, which can impact the drug product's performance.

3. Which regulatory bodies are most critical for API suppliers to be approved by for global market access? The US Food and Drug Administration (FDA) and the European Directorate for the Quality of Medicines & HealthCare (EDQM) are critical for global market access for API suppliers.

4. What are the main factors driving competition among API suppliers for these established drugs? Competition is driven by cost of production, quality and regulatory compliance, security of supply, and technical expertise in synthesis and impurity control.

5. Does the intellectual property landscape for trandolapril and verapamil hydrochloride APIs influence supplier selection? As these are mature APIs with expired molecular patents, the IP landscape primarily impacts manufacturing processes and potential patent-infringement claims, rather than the molecule itself. Suppliers must ensure their proprietary manufacturing routes do not infringe on existing process patents.

Citations

[1] Divi's Laboratories Limited. (n.d.). Retrieved from https://www.divislabs.com/ [2] Sun Pharmaceutical Industries Ltd. (n.d.). Retrieved from https://www.sunpharma.com/ [3] Laurus Labs Limited. (n.d.). Retrieved from https://www.lauruslabs.com/ [4] Dr. Reddy's Laboratories Ltd. (n.d.). Retrieved from https://www.drreddys.com/ [5] Neuland Laboratories Ltd. (n.d.). Retrieved from https://www.neuland.com/ [6] Granules India Ltd. (n.d.). Retrieved from https://www.granulesindia.com/ [7] Solara Active Pharma Sciences Limited. (n.d.). Retrieved from https://www.solarafarmascis.com/ [8] Industrias Farmaceuticas Alce, S.A.P.I. de C.V. (ALCE). (n.d.). Retrieved from https://www.alce.com.mx/